- Home
- ELUT vs TCRX Comparison
ELUT vs TCRX Comparison
Compare ELUT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELUT
- TCRX
- Stock Information
- Founded
- ELUT 2015
- TCRX 2018
- Country
- ELUT United States
- TCRX United States
- Employees
- ELUT N/A
- TCRX N/A
- Industry
- ELUT Medical Specialities
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ELUT Health Care
- TCRX Health Care
- Exchange
- ELUT Nasdaq
- TCRX Nasdaq
- Market Cap
- ELUT N/A
- TCRX 98.5M
- IPO Year
- ELUT 2020
- TCRX 2021
- Fundamental
- Price
- ELUT $2.64
- TCRX $1.35
- Analyst Decision
- ELUT Strong Buy
- TCRX Strong Buy
- Analyst Count
- ELUT 2
- TCRX 6
- Target Price
- ELUT $9.00
- TCRX $9.83
- AVG Volume (30 Days)
- ELUT 52.2K
- TCRX 437.3K
- Earning Date
- ELUT 03-06-2025
- TCRX 03-05-2025
- Dividend Yield
- ELUT N/A
- TCRX N/A
- EPS Growth
- ELUT N/A
- TCRX N/A
- EPS
- ELUT N/A
- TCRX N/A
- Revenue
- ELUT $24,375,000.00
- TCRX $2,816,000.00
- Revenue This Year
- ELUT $39.35
- TCRX $32.21
- Revenue Next Year
- ELUT $111.41
- TCRX $118.35
- P/E Ratio
- ELUT N/A
- TCRX N/A
- Revenue Growth
- ELUT N/A
- TCRX N/A
- 52 Week Low
- ELUT $2.28
- TCRX $1.34
- 52 Week High
- ELUT $5.24
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- ELUT 40.04
- TCRX 29.10
- Support Level
- ELUT $2.55
- TCRX $1.44
- Resistance Level
- ELUT $2.85
- TCRX $1.76
- Average True Range (ATR)
- ELUT 0.22
- TCRX 0.17
- MACD
- ELUT -0.05
- TCRX -0.01
- Stochastic Oscillator
- ELUT 9.89
- TCRX 1.82
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.